-
1
-
-
0016251063
-
Role of diabetes in congestive heart failure: the Framingham study
-
Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29-34.
-
(1974)
Am J Cardiol
, vol.34
, Issue.1
, pp. 29-34
-
-
Kannel, W.B.1
Hjortland, M.2
Castelli, W.P.3
-
2
-
-
77953821528
-
Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E et al.: diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
-
Emerging Risk Factors C. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E et al.: diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22.
-
(2010)
Lancet
, vol.375
, Issue.9733
, pp. 2215-2222
-
-
-
3
-
-
84930079243
-
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy
-
Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet. 2015;385(9982):2107-17.
-
(2015)
Lancet
, vol.385
, Issue.9982
, pp. 2107-2117
-
-
Gilbert, R.E.1
Krum, H.2
-
4
-
-
1442299811
-
Heart failure prevalence, incidence, and mortality in the elderly with diabetes
-
Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27(3):699-703.
-
(2004)
Diabetes Care
, vol.27
, Issue.3
, pp. 699-703
-
-
Bertoni, A.G.1
Hundley, W.G.2
Massing, M.W.3
Bonds, D.E.4
Burke, G.L.5
Goff, D.C.6
-
5
-
-
44949172981
-
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme
-
MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377-85.
-
(2008)
Eur Heart J
, vol.29
, Issue.11
, pp. 1377-1385
-
-
MacDonald, M.R.1
Petrie, M.C.2
Varyani, F.3
Ostergren, J.4
Michelson, E.L.5
Young, J.B.6
Solomon, S.D.7
Granger, C.B.8
Swedberg, K.9
Yusuf, S.10
-
6
-
-
70349881450
-
Intensive glucose control and macrovascular outcomes in type 2 diabetes
-
Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288-98.
-
(2009)
Diabetologia
, vol.52
, Issue.11
, pp. 2288-2298
-
-
Turnbull, F.M.1
Abraira, C.2
Anderson, R.J.3
Byington, R.P.4
Chalmers, J.P.5
Duckworth, W.C.6
Evans, G.W.7
Gerstein, H.C.8
Holman, R.R.9
Moritz, T.E.10
-
7
-
-
84928803853
-
The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies
-
Varas-Lorenzo C, Margulis AV, Pladevall M, Riera-Guardia N, Calingaert B, Hazell L, Romio S, Perez-Gutthann S. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc Disord. 2014;14:129.
-
(2014)
BMC Cardiovasc Disord
, vol.14
, pp. 129
-
-
Varas-Lorenzo, C.1
Margulis, A.V.2
Pladevall, M.3
Riera-Guardia, N.4
Calingaert, B.5
Hazell, L.6
Romio, S.7
Perez-Gutthann, S.8
-
8
-
-
77950507168
-
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
-
Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PD. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31(7):824-31.
-
(2010)
Eur Heart J
, vol.31
, Issue.7
, pp. 824-831
-
-
Komajda, M.1
McMurray, J.J.2
Beck-Nielsen, H.3
Gomis, R.4
Hanefeld, M.5
Pocock, S.J.6
Curtis, P.S.7
Jones, N.P.8
Home, P.D.9
-
9
-
-
84922257190
-
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
-
McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014;2(10):843-51.
-
(2014)
Lancet Diabetes Endocrinol
, vol.2
, Issue.10
, pp. 843-851
-
-
McMurray, J.J.1
Gerstein, H.C.2
Holman, R.R.3
Pfeffer, M.A.4
-
10
-
-
84988629139
-
Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes
-
Fitchett DH, Udell JA, Inzucchi SE. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur J Heart Fail. 2017;19(1):43-53.
-
(2017)
Eur J Heart Fail
, vol.19
, Issue.1
, pp. 43-53
-
-
Fitchett, D.H.1
Udell, J.A.2
Inzucchi, S.E.3
-
11
-
-
84883745765
-
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
-
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327-35.
-
(2013)
N Engl J Med
, vol.369
, Issue.14
, pp. 1327-1335
-
-
White, W.B.1
Cannon, C.P.2
Heller, S.R.3
Nissen, S.E.4
Bergenstal, R.M.5
Bakris, G.L.6
Perez, A.T.7
Fleck, P.R.8
Mehta, C.R.9
Kupfer, S.10
-
12
-
-
84883765959
-
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
-
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-26.
-
(2013)
N Engl J Med
, vol.369
, Issue.14
, pp. 1317-1326
-
-
Scirica, B.M.1
Bhatt, D.L.2
Braunwald, E.3
Steg, P.G.4
Davidson, J.5
Hirshberg, B.6
Ohman, P.7
Frederich, R.8
Wiviott, S.D.9
Hoffman, E.B.10
-
13
-
-
84937053742
-
Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
-
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232-42.
-
(2015)
N Engl J Med
, vol.373
, Issue.3
, pp. 232-242
-
-
Green, J.B.1
Bethel, M.A.2
Armstrong, P.W.3
Buse, J.B.4
Engel, S.S.5
Garg, J.6
Josse, R.7
Kaufman, K.D.8
Koglin, J.9
Korn, S.10
-
14
-
-
84930085787
-
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
-
Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067-76.
-
(2015)
Lancet
, vol.385
, Issue.9982
, pp. 2067-2076
-
-
Zannad, F.1
Cannon, C.P.2
Cushman, W.C.3
Bakris, G.L.4
Menon, V.5
Perez, A.T.6
Fleck, P.R.7
Mehta, C.R.8
Kupfer, S.9
Wilson, C.10
-
15
-
-
84859103180
-
The effect of glucagon-like peptide 1 on cardiovascular risk
-
Sivertsen J, Rosenmeier J, Holst JJ, Vilsboll T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol. 2012;9(4):209-22.
-
(2012)
Nat Rev Cardiol
, vol.9
, Issue.4
, pp. 209-222
-
-
Sivertsen, J.1
Rosenmeier, J.2
Holst, J.J.3
Vilsboll, T.4
-
16
-
-
84904007147
-
Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants
-
Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014;32(4):147-58.
-
(2014)
Cardiovasc Ther
, vol.32
, Issue.4
, pp. 147-158
-
-
Wu, S.1
Hopper, I.2
Skiba, M.3
Krum, H.4
-
17
-
-
84901188346
-
Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study
-
Oyama J, Ishizu T, Sato Y, Kodama K, Bando YK, Murohara T, Node K. Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study. Int J Cardiol. 2014;174(2):383-4.
-
(2014)
Int J Cardiol
, vol.174
, Issue.2
, pp. 383-384
-
-
Oyama, J.1
Ishizu, T.2
Sato, Y.3
Kodama, K.4
Bando, Y.K.5
Murohara, T.6
Node, K.7
-
18
-
-
84978123661
-
The effect of sitagliptin on carotid artery atherosclerosis in type 2 diabetes: the PROLOGUE randomized controlled trial
-
Oyama J, Murohara T, Kitakaze M, Ishizu T, Sato Y, Kitagawa K, Kamiya H, Ajioka M, Ishihara M, Dai K, et al. The effect of sitagliptin on carotid artery atherosclerosis in type 2 diabetes: the PROLOGUE randomized controlled trial. PLoS Med. 2016;13(6):e1002051.
-
(2016)
PLoS Med
, vol.13
, Issue.6
-
-
Oyama, J.1
Murohara, T.2
Kitakaze, M.3
Ishizu, T.4
Sato, Y.5
Kitagawa, K.6
Kamiya, H.7
Ajioka, M.8
Ishihara, M.9
Dai, K.10
-
19
-
-
29244432482
-
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology
-
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2005;18(12):1440-63.
-
(2005)
J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr
, vol.18
, Issue.12
, pp. 1440-1463
-
-
Lang, R.M.1
Bierig, M.2
Devereux, R.B.3
Flachskampf, F.A.4
Foster, E.5
Pellikka, P.A.6
Picard, M.H.7
Roman, M.J.8
Seward, J.9
Shanewise, J.S.10
-
20
-
-
0022588019
-
Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings
-
Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57(6):450-8.
-
(1986)
Am J Cardiol
, vol.57
, Issue.6
, pp. 450-458
-
-
Devereux, R.B.1
Alonso, D.R.2
Lutas, E.M.3
Gottlieb, G.J.4
Campo, E.5
Sachs, I.6
Reichek, N.7
-
21
-
-
29244432482
-
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology
-
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2005;18(12):1440-63.
-
(2005)
J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr
, vol.18
, Issue.12
, pp. 1440-1463
-
-
Lang, R.M.1
Bierig, M.2
Devereux, R.B.3
Flachskampf, F.A.4
Foster, E.5
Pellikka, P.A.6
Picard, M.H.7
Roman, M.J.8
Seward, J.9
Shanewise, J.S.10
-
22
-
-
84937227669
-
Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes
-
1727a-1727c
-
Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015; 36(27):1718-1727, 1727a-1727c.
-
(2015)
Eur Heart J
, vol.36
, Issue.27
, pp. 1718-1727
-
-
Seferovic, P.M.1
Paulus, W.J.2
-
23
-
-
65449125347
-
Changes in diastolic dysfunction in diabetes mellitus over time
-
From AM, Scott CG, Chen HH. Changes in diastolic dysfunction in diabetes mellitus over time. Am J Cardiol. 2009;103(10):1463-6.
-
(2009)
Am J Cardiol
, vol.103
, Issue.10
, pp. 1463-1466
-
-
From, A.M.1
Scott, C.G.2
Chen, H.H.3
-
24
-
-
84992361845
-
Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study
-
Maruhashi T, Higashi Y, Kihara Y, Yamada H, Sata M, Ueda S, Odawara M, Terauchi Y, Dai K, Ohno J, et al. Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study. Cardiovasc Diabetol. 2016;15(1):134.
-
(2016)
Cardiovasc Diabetol
, vol.15
, Issue.1
, pp. 134
-
-
Maruhashi, T.1
Higashi, Y.2
Kihara, Y.3
Yamada, H.4
Sata, M.5
Ueda, S.6
Odawara, M.7
Terauchi, Y.8
Dai, K.9
Ohno, J.10
-
25
-
-
84994050554
-
Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study
-
Tomiyama H, Miwa T, Kan K, Matsuhisa M, Kamiya H, Nanasato M, Kitano T, Sano H, Ohno J, Iida M, et al. Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study. Cardiovasc Diabetol. 2016;15(1):150.
-
(2016)
Cardiovasc Diabetol
, vol.15
, Issue.1
, pp. 150
-
-
Tomiyama, H.1
Miwa, T.2
Kan, K.3
Matsuhisa, M.4
Kamiya, H.5
Nanasato, M.6
Kitano, T.7
Sano, H.8
Ohno, J.9
Iida, M.10
-
26
-
-
84962090232
-
Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intima-media thickness evaluation (SPIKE): a randomized controlled trial
-
Mita T, Katakami N, Shiraiwa T, Yoshii H, Onuma T, Kuribayashi N, Osonoi T, Kaneto H, Kosugi K, Umayahara Y, et al. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intima-media thickness evaluation (SPIKE): a randomized controlled trial. Diabetes Care. 2016;39(3):455-64.
-
(2016)
Diabetes Care
, vol.39
, Issue.3
, pp. 455-464
-
-
Mita, T.1
Katakami, N.2
Shiraiwa, T.3
Yoshii, H.4
Onuma, T.5
Kuribayashi, N.6
Osonoi, T.7
Kaneto, H.8
Kosugi, K.9
Umayahara, Y.10
-
27
-
-
84962052181
-
Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A)
-
Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, et al. Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A). Diabetes Care. 2016;39(1):139-48.
-
(2016)
Diabetes Care
, vol.39
, Issue.1
, pp. 139-148
-
-
Mita, T.1
Katakami, N.2
Yoshii, H.3
Onuma, T.4
Kaneto, H.5
Osonoi, T.6
Shiraiwa, T.7
Kosugi, K.8
Umayahara, Y.9
Yamamoto, T.10
-
28
-
-
84924331804
-
Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes
-
Fontes-Carvalho R, Ladeiras-Lopes R, Bettencourt P, Leite-Moreira A, Azevedo A. Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes. Cardiovasc Diabetol. 2015;14:4.
-
(2015)
Cardiovasc Diabetol
, vol.14
, pp. 4
-
-
Fontes-Carvalho, R.1
Ladeiras-Lopes, R.2
Bettencourt, P.3
Leite-Moreira, A.4
Azevedo, A.5
-
29
-
-
84896092380
-
Molecular mechanisms of diabetic cardiomyopathy
-
Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57(4):660-71.
-
(2014)
Diabetologia
, vol.57
, Issue.4
, pp. 660-671
-
-
Bugger, H.1
Abel, E.D.2
-
30
-
-
84924298451
-
Targeting metabolic disturbance in the diabetic heart
-
Fuentes-Antras J, Picatoste B, Ramirez E, Egido J, Tunon J, Lorenzo O. Targeting metabolic disturbance in the diabetic heart. Cardiovasc Diabetol. 2015;14:17.
-
(2015)
Cardiovasc Diabetol
, vol.14
, pp. 17
-
-
Fuentes-Antras, J.1
Picatoste, B.2
Ramirez, E.3
Egido, J.4
Tunon, J.5
Lorenzo, O.6
-
31
-
-
84885844459
-
Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure
-
dos Santos L, Salles TA, Arruda-Junior DF, Campos LC, Pereira AC, Barreto AL, Antonio EL, Mansur AJ, Tucci PJ, Krieger JE, et al. Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. Circ Heart Fail. 2013;6(5):1029-38.
-
(2013)
Circ Heart Fail
, vol.6
, Issue.5
, pp. 1029-1038
-
-
Santos, L.1
Salles, T.A.2
Arruda-Junior, D.F.3
Campos, L.C.4
Pereira, A.C.5
Barreto, A.L.6
Antonio, E.L.7
Mansur, A.J.8
Tucci, P.J.9
Krieger, J.E.10
-
32
-
-
84981550375
-
The contributions of dipeptidyl peptidase IV to inflammation in heart failure
-
de Almeida Salles T, Zogbi C, de Lima TM, de Godoi Carneiro C, Garcez AT, Barbeiro HV, Antonio EL, Dos Santos L, da Costa Pereira A, Tucci PJ, et al. The contributions of dipeptidyl peptidase IV to inflammation in heart failure. Ame J Physiol Heart Circ Physiol. 2016;310(11):H1760-72.
-
(2016)
Ame J Physiol Heart Circ Physiol
, vol.310
, Issue.11
, pp. H1760-H1772
-
-
Almeida, S.T.1
Zogbi, C.2
Lima, T.M.3
Godoi, C.C.4
Garcez, A.T.5
Barbeiro, H.V.6
Antonio, E.L.7
Santos, L.8
Costa, P.A.9
Tucci, P.J.10
-
33
-
-
84867254999
-
Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions
-
Shigeta T, Aoyama M, Bando YK, Monji A, Mitsui T, Takatsu M, Cheng XW, Okumura T, Hirashiki A, Nagata K, et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation. 2012;126(15):1838-51.
-
(2012)
Circulation
, vol.126
, Issue.15
, pp. 1838-1851
-
-
Shigeta, T.1
Aoyama, M.2
Bando, Y.K.3
Monji, A.4
Mitsui, T.5
Takatsu, M.6
Cheng, X.W.7
Okumura, T.8
Hirashiki, A.9
Nagata, K.10
-
34
-
-
62949195390
-
Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction
-
Zaruba MM, Theiss HD, Vallaster M, Mehl U, Brunner S, David R, Fischer R, Krieg L, Hirsch E, Huber B, et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell. 2009;4(4):313-23.
-
(2009)
Cell Stem Cell
, vol.4
, Issue.4
, pp. 313-323
-
-
Zaruba, M.M.1
Theiss, H.D.2
Vallaster, M.3
Mehl, U.4
Brunner, S.5
David, R.6
Fischer, R.7
Krieg, L.8
Hirsch, E.9
Huber, B.10
-
35
-
-
77951168113
-
Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice
-
Sauve M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Husain M, Drucker DJ. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes. 2010;59(4):1063-73.
-
(2010)
Diabetes
, vol.59
, Issue.4
, pp. 1063-1073
-
-
Sauve, M.1
Ban, K.2
Momen, M.A.3
Zhou, Y.Q.4
Henkelman, R.M.5
Husain, M.6
Drucker, D.J.7
-
36
-
-
77951812608
-
The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA
-
Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol. 2010;298(5):H1454-65.
-
(2010)
Am J Physiol Heart Circ Physiol
, vol.298
, Issue.5
, pp. H1454-H1465
-
-
Ye, Y.1
Keyes, K.T.2
Zhang, C.3
Perez-Polo, J.R.4
Lin, Y.5
Birnbaum, Y.6
-
37
-
-
84865492997
-
Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus
-
Patil HR, Al Badarin FJ, Al Shami HA, Bhatti SK, Lavie CJ, Bell DS, O'Keefe JH. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110(6):826-33.
-
(2012)
Am J Cardiol
, vol.110
, Issue.6
, pp. 826-833
-
-
Patil, H.R.1
Al Badarin, F.J.2
Al Shami, H.A.3
Bhatti, S.K.4
Lavie, C.J.5
Bell, D.S.6
O'Keefe, J.H.7
-
38
-
-
84900410339
-
Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease
-
McCormick LM, Kydd AC, Read PA, Ring LS, Bond SJ, Hoole SP, Dutka DP. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease. Circ Cardiovasc Imaging. 2014;7(2):274-81.
-
(2014)
Circ Cardiovasc Imaging
, vol.7
, Issue.2
, pp. 274-281
-
-
McCormick, L.M.1
Kydd, A.C.2
Read, P.A.3
Ring, L.S.4
Bond, S.J.5
Hoole, S.P.6
Dutka, D.P.7
-
39
-
-
85019129876
-
Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure
-
2016 Nov 9. [Epub ahead of print].
-
Arturi F, Succurro E, Miceli S, Cloro C, Ruffo M, Maio R, Perticone M, Sesti G, Perticone F. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. Endocrine. 2016 Endocrine. 2016 Nov 9. [Epub ahead of print].
-
Endocrine. 2016 Endocrine
-
-
Arturi, F.1
Succurro, E.2
Miceli, S.3
Cloro, C.4
Ruffo, M.5
Maio, R.6
Perticone, M.7
Sesti G.Perticone, F.8
-
40
-
-
84934910233
-
Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial
-
Oe H, Nakamura K, Kihara H, Shimada K, Fukuda S, Takagi T, Miyoshi T, Hirata K, Yoshikawa J, Ito H. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. Cardiovasc Diabetol. 2015;14:83.
-
(2015)
Cardiovasc Diabetol
, vol.14
, pp. 83
-
-
Oe, H.1
Nakamura, K.2
Kihara, H.3
Shimada, K.4
Fukuda, S.5
Takagi, T.6
Miyoshi, T.7
Hirata, K.8
Yoshikawa, J.9
Ito, H.10
-
41
-
-
84908394848
-
Rossi da Silva ME: left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor-a pilot study
-
Nogueira KC, Furtado M, Fukui RT, Correia MR, Dos Santos RF, Andrade JL. Rossi da Silva ME: left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor-a pilot study. Diabetol Metab Syndr. 2014;6(1):103.
-
(2014)
Diabetol Metab Syndr
, vol.6
, Issue.1
, pp. 103
-
-
Nogueira, K.C.1
Furtado, M.2
Fukui, R.T.3
Correia, M.R.4
Santos, R.F.5
Andrade, J.L.6
-
42
-
-
84901462249
-
Cardiovascular actions of incretin-based therapies
-
Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114(11):1788-803.
-
(2014)
Circ Res
, vol.114
, Issue.11
, pp. 1788-1803
-
-
Ussher, J.R.1
Drucker, D.J.2
-
43
-
-
84969257362
-
Improved diastolic function in type 2 diabetes after a six month liraglutide treatment
-
Saponaro F, Sonaglioni A, Rossi A, Montefusco L, Lombardo M, Adda G, Arosio M. Improved diastolic function in type 2 diabetes after a six month liraglutide treatment. Diabetes Res Clin Pract. 2016;118:21-8.
-
(2016)
Diabetes Res Clin Pract
, vol.118
, pp. 21-28
-
-
Saponaro, F.1
Sonaglioni, A.2
Rossi, A.3
Montefusco, L.4
Lombardo, M.5
Adda, G.6
Arosio, M.7
-
44
-
-
84960100350
-
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
-
Li L, Li S, Deng K, Liu J, Vandvik PO, Zhao P, Zhang L, Shen J, Bala MM, Sohani ZN, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ (Clin Res ed). 2016;352:i610.
-
(2016)
BMJ (Clin Res ed)
, vol.352
-
-
Li, L.1
Li, S.2
Deng, K.3
Liu, J.4
Vandvik, P.O.5
Zhao, P.6
Zhang, L.7
Shen, J.8
Bala, M.M.9
Sohani, Z.N.10
-
45
-
-
84994475820
-
Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials
-
Rehman MB, Tudrej BV, Soustre J, Buisson M, Archambault P, Pouchain D, Vaillant-Roussel H, Gueyffier F, Faillie JL, Perault-Pochat MC, et al. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab. 2017;43(1):48-58.
-
(2017)
Diabetes Metab
, vol.43
, Issue.1
, pp. 48-58
-
-
Rehman, M.B.1
Tudrej, B.V.2
Soustre, J.3
Buisson, M.4
Archambault, P.5
Pouchain, D.6
Vaillant-Roussel, H.7
Gueyffier, F.8
Faillie, J.L.9
Perault-Pochat, M.C.10
|